AI Stocks Slide, Pharma Rallies; XLV Hits $177.19 Record

The rotation out of AI stocks and into healthcare reflects a broader reassessment of risk. The trigger this week was investor concern over the scale of AI capital expenditures and slowing revenue growth at Anthropic, which prompted selling across related technology names. As capital sought safety in consumer staples and U.S. Treasuries, the healthcare sector emerged as one of the biggest beneficiaries, with the State Street SPDR Health Care Select Sector ETF (XLV) touching an intraday record high of $177.19 on Thursday (Oct. 15) and gaining 5.6% over the past five trading sessions. Large-cap pharmaceutical companies, seen as offering stable operations and predictable earnings, have attracted the most flows.

Eli Lilly and AbbVie illustrate this dynamic. Lilly shares closed up 3.6% on Thursday at $1,251.61, the third-highest close in its history, with no specific clinical trial or deal driving the move—rather, it appears to follow a pattern where AI headwinds coincide with Lilly gains. The company's GLP-1 dominance and CEO Dave Ricks' disclosure of 40 deals worth $20 billion year-to-date, plus two novel weight-loss drugs entering regulatory review, reinforce its growth narrative. AbbVie, meanwhile, closed up 0.56% at $283.40, just a day after a record high, supported by new clinical data on Skyrizi's subcutaneous formulation that could extend patent protection and drive incremental sales.

The rally broadened to other large-cap biopharma names: Gilead Sciences and Amgen rose 7.7% and 7.0% over five sessions, respectively, despite no major news catalysts, suggesting capital rotation was the main driver. UnitedHealth Group surged 9.1% on solid third-quarter results. However, small-cap biotech lagged, with the SPDR S&P Biotech ETF (XBI) down 2.8% over the past month, underscoring investors' preference for the certainty premium offered by large pharmaceutical companies. This divergence highlights a market environment where stability and predictable earnings are being prioritized over high-risk, high-reward segments.